Future studies whenever feasible might continue to explore heterogeneity of treatment effects of GLP1 receptor agonists or SGLT2 inhibitors, especially in clinically relevant subgroups, across BMI strata, and across age strata, which may suggest opportunities to optimize personalized dementia risk mitigation based on risk profiles. The gene discussed is GLP1R; the disease is dementia.